Adv Drug Deliv Rev 59(2-3): 141-152

shRNA and siRNA Delivery to the Brain

William M. Pardridge, Dept. of Medicine, UCLA, Los Angeles, CA 90024;

Correspondence: Dr. William M. Pardridge, Dept. of Medicine, UCLA Warren Hall 13-164, 900 Veteran Ave., Los Angeles, CA 90024, Ph: (310) 825-8858, Fax: (310) 2-06-5163, ude.alcu.tendem@egdirdrapw

Publisher's Disclaimer

Abstract

The limiting factor in in vivo RNA interference (RNAi) is delivery. Drug delivery methods that are effective in cell culture may not be practical in vivo for intravenous RNAi applications. Nucleic acid drugs are highly charged and do not cross cell membranes by free diffusion. Therefore, the in vivo delivery of RNAi-therapeutics must using targeting technology that enables the RNAi therapeutic to traverse biological membrane barriers in vivo. For RNAi of the brain, the nucleic acid-based drug must first cross the brain capillary endothelial wall, which forms the blood-brain barrier (BBB) in vivo, and then traverse the brain cell plasma membrane. Similar to the delivery of non-viral gene therapies, plasmid DNA encoding for short hairpin RNA (shRNA) may be delivered to brain following intravenous administration with pegylated immunoliposomes (PILs). The plasmid DNA is encapsulated in a 100 nm liposome, which is pegylated, and conjugated with receptor specific targeting monoclonal antibodies (MAb). Weekly, intravenous RNAi with PILs enables a 90% knockdown of the human epidermal growth factor receptor, which results in a 90% increase in survival time in mice with intra-cranial brain cancer. Similar to the delivery of antisense agents, short interfering RNAi (siRNA) duplexes can be delivered with the combined use of targeting MAb’s and avidin-biotin technology. The siRNA is mono-biotinylated in parallel with the production of a conjugate of the targeting MAb and streptavidin. Intravenous RNAi requires the combined use of RNAi technology and a drug targeting technology that is effective in vivo.

Keywords: blood-brain barrier, RNAi, endothelium, transferrin receptor, insulin receptor, monoclonal antibody

Abstract

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Footnotes

References

1. McManus MT, Sharp PAGene silencing in mammals by small interfering RNAs. Nat Rev Genet. 2002;(3):737–747.[PubMed][Google Scholar]
2. Brightman MW, Reese TS, Feder N Assessment with the electron microscope of the permeability to peroxidase of cerebral endothelium and epithelium in mice and sharks. Capillary Permeability; Munksgaard, Copenhagen: 1970. p. 463. [PubMed][Google Scholar]
3. Pardridge WM Brain drug targeting; the future of brain drug development. Cambridge University Press; Cambridge, United Kingdom: 2001. pp. 1–370. [PubMed][Google Scholar]
4. Pardridge WMThe blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;(2):3–14.[Google Scholar]
5. Zhang Y, Pardridge WMRapid transferrin efflux from brain to blood across the blood-brain barrier. J Neurochem. 2001;(76):1597–1600.[PubMed][Google Scholar]
6. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WMTargeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;(292):1048–1052.[PubMed][Google Scholar]
7. Pardridge WM, Buciak JL, Friden PMSelective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther. 1991;(259):66–70.[PubMed][Google Scholar]
8. Pardridge WM, Kang YS, Buciak JL, Yang JHuman insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm Res. 1995;(12):807–816.[PubMed][Google Scholar]
9. Coloma MJ, et al Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res. 2000;(17):266–274.[PubMed][Google Scholar]
10. Wu D, Pardridge WMCentral nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharmacol Exp Ther. 1996;(279):77–83.[PubMed][Google Scholar]
11. Wu D, Pardridge WMNeuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A. 1999;(96):254–259.[Google Scholar]
12. Zhang Y, Pardridge WMConjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 2001;(889):49–56.[PubMed][Google Scholar]
13. Zhang Y, Pardridge WMNeuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke. 2001;(32):1378–1384.[PubMed][Google Scholar]
14. Song BW, Vinters HV, Wu D, Pardridge WMEnhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J Pharmacol Exp Ther. 2002;(301):605–610.[PubMed][Google Scholar]
15. Kurihara A, Pardridge WMImaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res. 1999;(59):6159–6163.[PubMed][Google Scholar]
16. Zhang Y, Pardridge WMDelivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther. 2005;(313):1075–1081.[PubMed][Google Scholar]
17. Shi N, Pardridge WMNoninvasive gene targeting to the brain. Proc Natl Acad Sci U S A. 2000;(97):7567–7572.[Google Scholar]
18. Shah N, Zhang S, Harada S, Smith RM, Jarett LElectron microscopic visualization of insulin translocation into the cytoplasm and nuclei of intact H35 hepatoma cells using covalently linked Nanogold-insulin. Endocrinology. 1995;(136):2825–2835.[PubMed][Google Scholar]
19. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WMReceptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med. 2002;(4):183–194.[PubMed][Google Scholar]
20. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WMIntravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism. Hum Gene Ther. 2003;(14):1–12.[PubMed][Google Scholar]
21. Pardridge WMGene targeting in vivo with pegylated immunoliposomes. Methods Enzymol. 2003;(373):507–528.[PubMed][Google Scholar]
22. Norman J, et al Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther. 2000;(7):1425–1430.[PubMed][Google Scholar]
23. Loisel S, Le Gall C, Doucet L, Ferec C, Floch VContribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes. Hum Gene Ther. 2001;(12):685–696.[PubMed][Google Scholar]
24. Elouahabi A, et al Free cationic liposomes inhibit the inflammatory response to cationic lipid-DNA complex injected intravenously and enhance its transfection efficiency. Mol Ther. 2003;(7):81–88.[PubMed][Google Scholar]
25. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A. 2001;(98):12754–12759.
26. Zhu C, Zhang Y, Pardridge WMWidespread expression of an exogenous gene in the eye after intravenous administration. Invest Ophthalmol Vis Sci. 2002;(43):3075–3080.[PubMed][Google Scholar]
27. Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WMOrgan-specific gene expression in the Rhesus monkey eye following intravenous non-viral gene transfer. Mol Vis. 2003;(9):465–472.[PubMed][Google Scholar]
28. Zhang Y, Schlachetzki F, Pardridge WMGlobal non-viral gene transfer to the primate brain following intravenous administration. Mol Ther. 2003;(7):11–18.[PubMed][Google Scholar]
29. Chu C, Zhang Y, Boado RJ, Pardridge WMDecline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharm Res. 2006 in press. [[PubMed][Google Scholar]
30. Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WMNormalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum Gene Ther. 2004;(15):339–350.[PubMed][Google Scholar]
31. Naeser P. Insulin receptors in human ocular tissues. Immunohistochemical demonstration in normal and diabetic eyes. Ups J Med Sci. 1997;(102):35–40.[PubMed]
32. Shi N, Boado RJ, Pardridge WMReceptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res. 2001;(18):1091–1095.[PubMed][Google Scholar]
33. Zhang Y, Boado RJ, Pardridge WMIn vivo knockdown of gene expression in brain cancer with intravenous RNAi in adult rats. J Gene Med. 2003;(5):1039–1045.[PubMed][Google Scholar]
34. Kuan CT, Wikstrand CJ, Bigner DDEGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001;(8):83–96.[PubMed][Google Scholar]
35. Nicholson RI, Gee JM, Harper MEEGFR and cancer prognosis. Eur J Cancer. 2001;37(Suppl 4):S9–15.[PubMed][Google Scholar]
36. Abe T, et al PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 2003;(63):2300–2305.[PubMed][Google Scholar]
37. Zhang Y, et al Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res. 2004;(10):3667–3677.[PubMed][Google Scholar]
38. Zhang Y, Zhu C, Pardridge WMAntisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther. 2002;(6):67–72.[PubMed][Google Scholar]
39. Wu CH, Wilson JM, Wu GYTargeting genes: delivery and persistent expression of a foreign gene driven by mammalian regulatory elements in vivo. J Biol Chem. 1989;(264):16985–16987.[PubMed][Google Scholar]
40. Kwoh DY, et al Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim Biophys Acta. 1999;(1444):171–190.[PubMed][Google Scholar]
41. Vehaskari VM, Chang CT, Stevens JK, Robson AM. The effects of polycations on vascular permeability in the rat. A proposed role for charge sites. J Clin Invest. 1984;(73):1053–1061.
42. Green NMAvidin. Adv Protein Chem. 1975;(29):85–133.[PubMed][Google Scholar]
43. Suzuki T, et al Imaging endogenous gene expression in brain cancer in vivo with 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med. 2004;(45):1766–1775.[PubMed][Google Scholar]
44. Tidd DM, Warenius HMPartial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups. Br J Cancer. 1989;(60):343–350.[Google Scholar]
45. Marcus-Sekura CJ, Woerner AM, Shinozuka K, Zon G, Quinnan GV., Jr Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages. Nucleic Acids Res. 1987;(15):5749–5763.
46. Ho PT, Ishiguro K, Wickstrom E, Sartorelli ACNon-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate oligodeoxynucleotides. Antisense Res Dev. 1991;(1):329–342.[PubMed][Google Scholar]
47. Stein CA, Cheng YCAntisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993;(261):1004–1012.[PubMed][Google Scholar]
48. Cossum PA, et al Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993;(267):1181–1190.[PubMed][Google Scholar]
49. Wu D, Boado RJ, Pardridge WMPharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther. 1996;(276):206–211.[PubMed][Google Scholar]
50. Garner P, Sherry B, Moilanen S, Huang YIn vitro stability of alpha-helical peptide nucleic acids (alphaPNAs) Bioorg Med Chem Lett. 2001;(11):2315–2317.[PubMed][Google Scholar]
51. Pardridge WM, Boado RJ, Kang YSVector-mediated delivery of a polyamide (“peptide”) nucleic acid analogue through the blood-brain barrier in vivo. Proc Natl Acad Sci U S A. 1995;(92):5592–5596.[Google Scholar]
52. Chiu YL, Rana TMRNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell. 2002;(10):549–561.[PubMed][Google Scholar]
53. Penichet ML, Kang YS, Pardridge WM, Morrison SL, Shin SU. An Anti-transferrin receptor antibody-avidin fusion protein serves as a delivery vehicle for effective brain targeting in an animal model. Initial applications in antisense drug delivery to the brain. J Immunol. 1999;(163):4421–4426.[PubMed]
54. Zhu C, et al Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med. 2004;(6):906–912.[PubMed][Google Scholar]